open access

Vol 80, No 2 (2022)
Short communication
Published online: 2021-12-06
Get Citation

SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints

Josip A Borovac12, Tina Kurir13, Ivona Mustapic2, Marko Kumric1, Josko Bozic1, Duska Glavas2, Domenico D’Amario4
DOI: 10.33963/KP.a2021.0172
·
Pubmed: 34870320
·
Kardiol Pol 2022;80(2):198-201.
Affiliations
  1. Department of Pathophysiology, School of Medicine, University of Split, Split, Croatia
  2. Clinic for Heart and Vascular Diseases, University Hospital of Split, Split, Croatia
  3. Department of Endocrinology and Diabetology, University Hospital of Split, Split, Croatia
  4. Department of Cardiovascular and Thoracic Sciences, IRCCS Fondazione Policlinico A Gemelli, Universita Cattolica Sacro Cuore, Rome, Italy

open access

Vol 80, No 2 (2022)
Short communication
Published online: 2021-12-06

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 80, No 2 (2022)

Article type

Short communication

Pages

198-201

Published online

2021-12-06

Page views

875

Article views/downloads

498

DOI

10.33963/KP.a2021.0172

Pubmed

34870320

Bibliographic record

Kardiol Pol 2022;80(2):198-201.

Authors

Josip A Borovac
Tina Kurir
Ivona Mustapic
Marko Kumric
Josko Bozic
Duska Glavas
Domenico D’Amario

References (13)
  1. de Leeuw AE, de Boer RA. Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects. Eur Heart J Cardiovasc Pharmacother. 2016; 2(4): 244–255.
  2. Kluger AY, Tecson KM, Lee AY, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019; 18(1): 99.
  3. Nessler J, Siniarski A, Leszek P, et al. Reviewers. Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction. Kardiol Pol. 2021; 79(3): 363–370.
  4. McMurray J, Solomon S, Inzucchi S, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995–2008.
  5. Anker SD, Butler J, Filippatos G, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383(15): 1413–1424.
  6. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019; 139(22): 2528–2536.
  7. Szarek M, Bhatt DL, Steg PhG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021; 384(2): 117–128.
  8. Butler J, Filippatos G, Siddiqi TJ, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail. 2019; 21(10): 1279–1287.
  9. Singh M, Kumar A. Risks associated with SGLT2 inhibitors: an overview. Curr Drug Saf. 2018; 13(2): 84–91.
  10. Bersoff-Matcha SJ, Chamberlain C, Cao C, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019; 170(11): 764–769.
  11. Puckrin R, Saltiel MP, Reynier P, et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018; 55(5): 503–514.
  12. Dave CV, Schneeweiss S, Kim D, et al. Sodium-Glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019; 171(4): 248–256.
  13. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl